Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
BURLINGTON, Mass., Feb. 28, 2018 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the Raymond James 39th Annual Institutional Investors Conference in Orlando, Florida. Dr. Clayman is scheduled to present at 8:05 a.m Eastern Time on Tuesday, March 6, 2018. Investors can access the live webcast and subsequent archived recording of the presentation by visiting the Flexion website at http://ir.flexiontherapeutics.com
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Flexion was named one of The Boston Business Journal's 2017 Best Places to Work and one of the Top Places to Work in Massachusetts by The Boston Globe.
Corporate Contact:
Scott Young
Vice President, Corporate Communications and Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
[email protected]
